New drug cocktail shows promise for rare sarcomas
NCT ID NCT04216953
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a combination of two drugs, cobimetinib and atezolizumab, in children and adults with advanced soft tissue sarcoma that has spread. The goal was to see if the combo is safe and can stop tumors from growing. About 229 people took part, and researchers measured how many had their disease controlled after 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cobimetinib (a MEK inhibitor) and atezolizumab (a PDL1 inhibitor)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced soft tissue sarcoma, potentially slowing tumor growth.
What could go wrong
This is an early-phase trial with a small number of patients, so results may not lead to a standard treatment. Side effects from the drug combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69008, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Hôpital de la Timone
Marseille, 13385, France
-
Institut Curie
Paris, France
-
Institut Gustave Roussy
Villejuif, 94800, France
-
Institut de Cancérologie de l'Ouest
Angers, 49055, France